Maxim Group Forecasts Strong Price Appreciation for Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare (NASDAQ:SRTS) had its price target hoisted by Maxim Group from $12.00 to $14.00 in a note issued to investors on Friday,Briefing.com Automated Import reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target would suggest a potential upside of 92.04% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sensus Healthcare in a research note on Monday, August 12th.

Sensus Healthcare Price Performance

Shares of SRTS stock opened at $7.29 on Friday. The firm has a market cap of $119.48 million, a price-to-earnings ratio of 17.78 and a beta of 1.04. The stock’s fifty day simple moving average is $6.30 and its 200 day simple moving average is $5.90. Sensus Healthcare has a one year low of $1.91 and a one year high of $7.49.

Institutional Trading of Sensus Healthcare

Several hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its position in Sensus Healthcare by 128.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after buying an additional 93,511 shares during the last quarter. Chapin Davis Inc. acquired a new stake in Sensus Healthcare in the second quarter worth about $53,000. Renaissance Technologies LLC boosted its stake in shares of Sensus Healthcare by 34.4% in the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after purchasing an additional 100,294 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Sensus Healthcare during the 2nd quarter worth approximately $156,000. Finally, Sachetta LLC raised its stake in shares of Sensus Healthcare by 12.9% during the second quarter. Sachetta LLC now owns 118,354 shares of the company’s stock worth $631,000 after buying an additional 13,544 shares during the last quarter. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.